

Date: 23/11/2022

To  
Department of Corporate Services,  
BSE Limited,  
Floor 25, P J Tower,  
Dalal Street,  
Mumbai - 400001.

**Scrip Code: 526445**

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015- Acquisition of a company by IBL Healthcare Limited, a wholly owned subsidiary of Indrayani Biotech Limited.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we are glad to inform that M/S IBL Healthcare Limited, a wholly owned subsidiary has acquired 52,970 equity shares, constituting 51% of total no of equity shares, of M/S India Home Health Care Private Limited ("IHHCP"). Thus, IHHCP has become a subsidiary company of IBL Healthcare Limited.

A Brief note of M/s India Home Health Care Private Limited is given in Annexure I.

The details of acquisition are given in Annexure II.

We request you to take this on your record.

Thanking you,

**For Indrayani Biotech Limited**

**Kasiraman Sayee Sundar**  
**Managing Director**  
**DIN: 01295584**

## ANNEXURE I

### Brief about India Home Health Care Private Limited



- India Home Health Care Private Limited (“IHCPL”) was established in 2009 for providing health care related services from the comfort of patient’s home with a vision to touch million lives positively.



- IHCPL provides services such as, Orthopedic care, Cancer Care, Critical Care, Neuro care, Tracheostomy and Ventilator care, Palliative Care, Geriatric Care, Post-Surgical Care and Wellness Services.
- IHCPL’s advanced technology solution provides remote health care services which will be beneficial for the patients without travelling to hospital and incurring related expenses.
- IHCPL is fast becoming the reliable partner for leading Clinical Research Organizations (CRO) in the USA and Europe, conducting Clinical Trials, having already made significant inroads into this segment, under the brand name **Avatar**.
- **Avatar** is targeting a revenue of around US\$ 6 Million in the next 36 months from the current run rate of US\$ 500 thousand.
- IHCPL is launching state of the art assisted living center in March 2023, with a vision to expand to 1000 units in the next 24 months.
- IHCPL is setting up a unique call center for assisting pharma companies in their patient support programs and operations are expected to commence in Q1 2023.
- IHCPL team, comprising eminent healthcare professionals from various streams, has acquired state of the art skills in collaboration with Bayada USA (largest home healthcare company with revenue of over US\$ 3 billion) who happens to be an investor as well as knowledge partner for IHCPL.
- IHCPL, to accomplish highest quality standards, has set up a training institute with advanced AI powered medical mannequin, for simulating all the critical conditions which can occur in a patient. All the medical staff of the company go through rigorous and comprehensive training before starting to serve the patients.
- IHCPL is targeting a revenue of INR 1 billion in the next 36 months.



**Annexure II**

**Details with respect to the acquisition as required under Regulation 30(6) read with Schedule III, Part A, Para A (1) of the SEBI Listing Regulations and the SEBI Circular CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015**

**Acquisition of a company in India:**

Name of the target entity, details in brief such as size, turnover etc.,	India Home Health Care Private Limited
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The transaction is within arm's length. There are no related parties involved in the transaction.
Industry to which the entity being acquired belongs;	Healthcare
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The company is becoming a subsidiary to our Wholly owned subsidiary, IBL Healthcare Limited. The vertical creates an immense intrinsic value to the company.
Brief details of any governmental or regulatory approvals required for the acquisition	NA
Indicative time period for completion of the acquisition;	On or before November 23, 2022.
Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration.
Cost of acquisition or the price at which the shares are acquired;	Rs. 52,96,911/-
Percentage of shareholding /control acquired and / or number of shares acquired	Percentage of holding: 51% No. of equity shares: 52,970
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Date of incorporation: 20/11/2009 Turnover for past 3 years FY 21-22: Rs. 4,95,34,010 FY 20-21: Rs. 5,31,57,099 FY 19-20: Rs. 5,27,13,536  The company is incorporated and existing in India